STAG2 and metastatic neoplasm: There was no statistically significant association between STAG2 expression and EFS among patients with metastatic disease (P = 0.11); however, patients with STAG2 loss of expression had worse OS (5-year OS was 58.5% for expressed and 16.7% for lost, P = 0.0077; Fig. 2c, d).